(3s)-3-[[(1,1-二甲基乙氧基)羰基]氨基]-7-[[(苯基甲氧基)羰基]氨基]-庚酸 | 346694-77-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3s)-3-[[(1,1-二甲基乙氧基)羰基]氨基]-7-[[(苯基甲氧基)羰基]氨基]-庚酸
• 中文别名: NΒ-BOC-NΩ-Z-L-Β-高赖氨酸；(S)-3-(BOC-氨基)-7-(Z-氨基)庚酸
• 英文名称: (S)-7-(benzyloxycarbonylamino)-3-(tert-butyloxycarbonylamino)heptanoic acid
• 英文别名: (S)-3-tert-butoxycarbonylamino-7-benzyloxycarbonylaminoheptanoic acid；Boc-L-β-HoLys(Cbz)-OH；(S)-3-([(tert-butoxy)carbonyl]amino)-7-([(tert-butoxy)carbonyl]amino)heptanoic acid；Boc-(S)-β3-HLys(2-Cl-Z)-OH；(S)-7-(((Benzyloxy)carbonyl)amino)-3-((tert-butoxycarbonyl)amino)heptanoic acid；(3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-7-(phenylmethoxycarbonylamino)heptanoic acid
• CAS: 346694-77-7
• 化学式: C₂₀H₃₀N₂O₆
• 分子量: 394.468
• InChiKey: MAHOLRAVFZCBFL-INIZCTEOSA-N

物化性质

• 沸点：
  599.0±50.0 °C(Predicted)
• 密度：
  1.160±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2924299090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
: Boc-β-Homolys(Z)-OH
Product name
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 346694-77-7

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : (S)-3-(Boc-amino)-7-(Z-amino)heptanoic acid
Nβ-Boc-Nω-Z-L-β-homolysine
Formula : C20H30N2O6
Molecular Weight : 394,46 g/mol
CAS-No. : 346694-77-7
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: beige
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (3s)-3-[[(1,1-二甲基乙氧基)羰基]氨基]-7-[[(苯基甲氧基)羰基]氨基]-庚酸 在 哌啶 、 palladium 10% on activated carbon 、 氢气 、 碳酸氢钠 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 31.5h， 生成
  参考文献：
  名称：

  Synthesis of Androprostamine A and Resormycin

  摘要：

  我们完成了由微生物产生的抗前列腺癌肽类天然产物安托前列腺素 A（1）和雷米霉素（3）的合成。利用 Horner-Wadsworth-Emmons 反应，以合理的 Z 选择性从相应的膦酸盐合成了这些化合物的特征烯酰胺结构。

  DOI：

  10.1248/cpb.c16-00207
• 作为产物：
  描述：

  (S)-7-Benzyloxycarbonylamino-3-tert-butoxycarbonylamino-heptanoic acid methyl ester 在 potassium carbonate 作用下， 以 甲醇 、 水 为溶剂， 生成 (3s)-3-[[(1,1-二甲基乙氧基)羰基]氨基]-7-[[(苯基甲氧基)羰基]氨基]-庚酸
  参考文献：
  名称：

  衍生自具有抗HIV活性的α-，β-和γ-氨基酸的2,2'-二硫代双苯甲酰胺：合成与构效关系。

  摘要：

  含有高度保守的逆转录病毒锌指的核衣壳蛋白（NCp7）在人类免疫缺陷病毒（HIV）生命周期的早期和晚期都是必不可少的，并且是AIDS治疗的新目标。HIV-1 NCp7是基本的55个氨基酸氨基酸蛋白，在两侧各含两个C（X）2C（X）4H（X）4C基序锌指。先前已报道2,2'-二硫代双苯甲酰胺从这些NCp7锌指中释放锌，并抑制HIV复制。具体而言，衍生自简单氨基酸的2,2'-二硫代双苯甲酰胺显示出良好的抗病毒活性。苯并异噻唑酮3（2的环状衍生物）被选为临床试验中的艾滋病治疗剂。本文中我们报告了2,2'的合成和抗病毒活性，包括治疗指数 衍生自α-，β-和γ-氨基酸的β-二硫代双苯甲酰胺。电喷雾电离质谱法用于研究这些化合物的锌喷射活性。在α-氨基酸衍生的2,2'-二硫代双苯甲酰胺中，发现含有烷基侧链的类似物具有良好的治疗指数，具有抗病毒活性。发现衍生自β-和γ-氨基酸的2,2'-二硫代双苯甲酰胺比α

  DOI：

  10.1016/s0968-0896(98)00118-7

文献信息

• Synthesis of Optically Active β-Amino Acid <i>N</i>-Carboxyanhydrides
  作者：Jianjun Cheng、Joseph W. Ziller、Timothy J. Deming

  DOI：10.1021/ol000122w

  日期：2000.6.1

  general synthesis of optically active beta-amino acid N-carboxyanhydrides (beta-NCAs) through cyclization of N(beta)-Boc or N(beta)-Cbz beta-amino acids using phosphorus tribromide. The formation of beta-NCAs was confirmed by spectroscopy as well as an X-ray structural determination of beta-homoalanine-N-carboxyanhydride. The beta-NCA molecules could be polymerized in good yield to give optically active

  已经开发了通过使用三溴化磷将Nβ-Boc或Nβ-Cbzβ-氨基酸环化来一般合成旋光性β-氨基酸N-羧基酸酐（β-NCA）的方法。β-NCA的形成已通过光谱法以及β-高丙氨酸-N-羧基酸酐的X射线结构测定得到了证实。β-NCA分子可以以高收率聚合，以产生在溶液中采用稳定手性构象的旋光性聚（β-肽）。例如，通过L-β-高苯丙氨酸-N-羧基酸酐的聚合来合成螺旋低聚物（L-β-高苯丙氨酸）。
• Tantalum-Catalyzed Amidation of Amino Acid Homologues
  作者：Wataru Muramatsu、Hisashi Yamamoto

  DOI：10.1021/jacs.9b08415

  日期：2019.12.4

  tantalum-catalyzed solvent-free approach for the construction of amide bonds with 1-(trimethylsilyl)imidazole is developed, and the mild reaction conditions are applicable to a wide variety of electrophilic amino acid homologs. This approach delivers a new class of peptides in high yields without any epimerization.

  开发了一种钽催化的无溶剂方法，用于与 1-（三甲基甲硅烷基）咪唑构建酰胺键，并且反应条件温和，适用于多种亲电氨基酸同系物。这种方法以高产率提供了一类新的肽，而没有任何差向异构化。
• ANTIBACTERIAL AMIDE MACROCYCLES IV
  申请人：Endermann Rainer

  公开号：US20080076745A1

  公开（公告）日：2008-03-27

  The invention relates to antibacterial amide macrocycles and processes for their preparation, their use for the treatment and/or prophylaxis of diseases and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially bacterial infections.

  该发明涉及抗菌酰胺大环化合物及其制备过程，其用于治疗和/或预防疾病以及用于制造治疗和/或预防疾病，特别是细菌感染的药物。
• Compounds That Inhibit Replication Of Human Immunodeficiency Virus
  申请人：Balzarini Maria Rene Jan

  公开号：US20080076824A1

  公开（公告）日：2008-03-27

  The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HUV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.

  本发明涉及一种新型化合物类别的发现，该类化合物能够抑制人类免疫缺陷病毒（HIV）的复制，并提供了鉴定这些化合物的方法。具体来说，发现经酶法制备的α-羟基甘氨酰胺和人工合成的α-羟基甘氨酰胺能够抑制HIV在人血清中的复制。实施例包括鉴定抑制HUV的改性甘氨酰胺化合物的方法，分离和合成改性甘氨酰胺化合物的方法，以及包含这些化合物的治疗组合物。
• Antibacterial amide macrocycles IV
  申请人：AiCuris GmbH & Co. KG

  公开号：US07446102B2

  公开（公告）日：2008-11-04

  The invention relates to antibacterial amide macrocycles and processes for their preparation, their use for the treatment and/or prophylaxis of diseases and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially bacterial infections.

  本发明涉及抗菌酰胺大环化合物及其制备方法，以及它们用于治疗和/或预防疾病的用途，以及用于制造治疗和/或预防疾病，特别是细菌感染的药物的用途。